{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:48Z","timestamp":1761895308244,"version":"3.44.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:36:19Z","timestamp":1311564979000},"page":"172-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance"],"prefix":"10.1053","volume":"48","author":[{"given":"Christiane","family":"Pott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.05.002_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib3","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib5","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-07-1371","article-title":"Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication","volume":"14","author":"Bosch","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000077566","article-title":"Significance of minimal residual disease in lymphoid malignancies","volume":"112","author":"Bruggemann","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib12","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/sj.leu.2400841","article-title":"Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response","volume":"11","author":"Foroni","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib14","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib15","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","article-title":"Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value","volume":"101","author":"Vidriales","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.leu.2403348","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib17","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib18","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"Bottcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","article-title":"Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation","volume":"18","author":"Bottcher","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib22","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/sj.leu.2402584","article-title":"Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation","volume":"16","author":"Sanchez","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/leu.2010.160","article-title":"Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping","volume":"24","author":"Costa","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib24","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/ijc.23883","article-title":"Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma","volume":"123","author":"Brizova","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2011.05.002_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.leu.2404479","article-title":"Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets","volume":"21","author":"Evans","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib26","first-page":"93","article-title":"Analysis of immunoglobulin and T cell receptor genes","volume":"198","author":"van Dongen","year":"1991","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(91)90246-9","article-title":"Analysis of immunoglobulin and T cell receptor genes","volume":"198","author":"van Dongen","year":"1991","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.leu.2404467","article-title":"Improved reliability of lymphoma diagnostics via PCR-based clonality testing\u2014report of the BIOMED-2 Concerted Action BHM4-CT98-3936","volume":"21","author":"van Krieken","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1365-2141.1997.2133030.x","article-title":"Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma","volume":"98","author":"Kurokawa","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2011.05.002_bib31","first-page":"471","article-title":"Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies","volume":"9","author":"Aubin","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib32","first-page":"840","article-title":"Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias","volume":"9","author":"Linke","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib33","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib34","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.leu.2401831","article-title":"Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR","volume":"14","author":"Bruggemann","year":"2000","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/sj.leu.2401172","article-title":"Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas","volume":"12","author":"Pott","year":"1998","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib39","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib40","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib42","first-page":"679","article-title":"Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease","volume":"91","author":"van der Velden","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib43","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib44","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","article-title":"PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2011.05.002_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/5.suppl_1.S71","article-title":"Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement","volume":"5","author":"Williams","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1023\/A:1008242729509","article-title":"Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas","volume":"9","author":"Siebert","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib47","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V78.2.493.493","article-title":"Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes","volume":"78","author":"Williams","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib49","first-page":"341","article-title":"Mantle cell\/centrocytic lymphoma: molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR","volume":"194","author":"Williams","year":"1995","journal-title":"Curr Top Microbiol Immunol"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2011.05.002_bib50","first-page":"5541s","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma","volume":"52","author":"Williams","year":"1992","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib51","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib52","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V81.11.3063.3063","article-title":"Rearrangement and overexpression of the BCL-1\/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias","volume":"81","author":"Rimokh","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib53","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/blood.V83.12.3689.3689","article-title":"Rearrangement of CCND1 (BCL1\/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib54","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"229","article-title":"Mature B-cell neoplasms: mantle cell lymphoma","author":"Swerdlow","year":"2008"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades","volume":"33","author":"Swerdlow","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib56","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","article-title":"A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors","volume":"11","author":"Voena","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib57","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2401575","article-title":"Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)","volume":"13","author":"Olsson","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib60","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib61","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib62","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib63","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib64","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib65","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib66","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V85.6.1596.bloodjournal8561596","article-title":"High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting","volume":"85","author":"Corradini","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","article-title":"Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells","volume":"17","author":"Corradini","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib68","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib69","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1704212","article-title":"Ex vivo B cell depletion using the Eligix B cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma","volume":"32","author":"Friedberg","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib70","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1701637","article-title":"Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?","volume":"23","author":"Jacquy","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib72","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.leu.2401488","article-title":"Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions","volume":"13","author":"Tarella","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib73","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib74","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP prior to autologous stem cell transplantation induces higher rates of molecular remission than R-CHOP in younger patients with MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract 965]","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib77","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma [abstract]","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib78","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib79","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/10428199909167400","article-title":"Clonality assessment in blood of patients with mantle cell lymphoma","volume":"32","author":"Bertoni","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib80","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.05.002_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:46Z","timestamp":1758522046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000515"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.05.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}